APTN on OTC
ADAPTIN BIO, INC.
ADAPTIN BIO, INC. is an American biological products company based in Charlotte, listed on OTC (APTN).1
Price unavailable
Last updated Oct 21, 2026.
Overview
- TickerAPTN on OTC1
- IndustryBiological Products, (No Diagnostic Substances)1
- HeadquartersCharlotte, North Carolina1
- Incorporated inDE2
- Business address3540 Toringdon Way, Suite 200, #250, Charlotte, Nc 282772
- Filer categoryNon-accelerated filer, Smaller reporting company, Emerging growth company2
- Legal formCorporation
See how the biggest companies compare on our leaderboards
30, 2025 (“Merger Sub”), and Adaptin Bio Operating Corporation (formerly “Adaptin Bio, Inc.”) (the “Merger”).3 From its latest annual report
Financials
From the company’s reports to the SEC. Every number links to the filing it came from.
Financial statements
Every line of the income statement as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Research and development | $1.8M | $1.8M |
| General and administrative | $3.6M | $745.3K |
| Total Operating Expenses | $5.4M | $2.6M |
| Loss from Operations | -$5.4M | -$2.6M |
| Interest expense | $72.7K | $341.0K |
| Loss on change in fair value of derivative liabilities | $6.3K | $17.1K |
| Loss (Gain) on extinguishment of debt | -$326.3K | $194.5K |
| Total Other Expense (Income), net | -$247.4K | $552.7K |
| Loss Before Provision for Income Taxes | -$5.2M | -$3.1M |
| Net Loss | -$5.2M | -$3.1M |
| Basic (in Dollars per share) | -$0.66 | -$0.96 |
| Diluted (in Dollars per share) | -$0.66 | -$0.96 |
| Basic (in Shares) | 7.8M shares | 3.2M shares |
| Diluted (in Shares) | 7.8M shares | 3.2M shares |
No quarter-by-quarter statement was filed.
Every line of the balance sheet as filed: the last 2 fiscal years (annual) or 2 quarters (quarterly), latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $459.2K | $34.1K |
| Prepaid expenses and other current assets | $160.0K | $11.5K |
| Total Current Assets | $619.2K | $45.5K |
| Deferred equity issuance costs | $193.9K | |
| Total Assets | $619.2K | $239.4K |
| Accounts payable- trade | $1.5M | $1.4M |
| Accrued expenses | $596.5K | $1.0M |
| Convertible notes payable, net of debt issuance costs and discounts | $1.2M | |
| Derivative liability arising from convertible notes payable | $545.0K | |
| Accrued interest | $134.9K | |
| Total Current Liabilities | $2.1M | $4.3M |
| Total Liabilities | $2.1M | $4.3M |
| Common stock, $0.0001 par value, 50,000,000 shares authorized, 8,655,829 and 3,249,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $866 | $325 |
| Additional paid-in capital | $7.8M | $23.8K |
| Accumulated deficit | -$9.3M | -$4.1M |
| Total Stockholders Deficit | -$1.5M | -$4.1M |
| Total Liabilities and Stockholders Deficit | $619.2K | $239.4K |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares |
| Preferred stock, share outstanding (in Shares) | 0 shares | 0 shares |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
| Common stock, shares authorized (in Shares) | 50.0M shares | 50.0M shares |
| Common stock, shares issued (in Shares) | 8.7M shares | 3.2M shares |
| Common stock, shares outstanding (in Shares) | 8.7M shares | 3.2M shares |
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Cash and cash equivalents | $459.2K | $34.1K |
| Prepaid expenses and other current assets | $160.0K | $11.5K |
| Total Current Assets | $619.2K | $45.5K |
| Deferred equity issuance costs | $193.9K | |
| Total Assets | $619.2K | $239.4K |
| Accounts payable- trade | $1.5M | $1.4M |
| Accrued expenses | $596.5K | $1.0M |
| Convertible notes payable, net of debt issuance costs and discounts | $1.2M | |
| Derivative liability arising from convertible notes payable | $545.0K | |
| Accrued interest | $134.9K | |
| Total Current Liabilities | $2.1M | $4.3M |
| Total Liabilities | $2.1M | $4.3M |
| Common stock, $0.0001 par value, 50,000,000 shares authorized, 8,655,829 and 3,249,999 shares issued and outstanding as of December 31, 2025 and 2024, respectively | $866 | $325 |
| Additional paid-in capital | $7.8M | $23.8K |
| Accumulated deficit | -$9.3M | -$4.1M |
| Total Stockholders Deficit | -$1.5M | -$4.1M |
| Total Liabilities and Stockholders Deficit | $619.2K | $239.4K |
| Preferred stock, par value (in Dollars per share) | $0.00 | $0.00 |
| Preferred stock, shares authorized (in Shares) | 10.0M shares | 10.0M shares |
| Preferred stock, shares issued (in Shares) | 0 shares | 0 shares |
| Preferred stock, share outstanding (in Shares) | 0 shares | 0 shares |
| Common stock, par value (in Dollars per share) | $0.00 | $0.00 |
| Common stock, shares authorized (in Shares) | 50.0M shares | 50.0M shares |
| Common stock, shares issued (in Shares) | 8.7M shares | 3.2M shares |
| Common stock, shares outstanding (in Shares) | 8.7M shares | 3.2M shares |
Cash flow is reported year to date, not quarter by quarter, so there are no separate quarterly figures.
Every line of the cash flow as filed: the last 2 fiscal years, latest first.5
| Period ending | 2025-12-31 | 2024-12-31 |
|---|---|---|
| Net Loss | -$5.2M | -$3.1M |
| Amortization of debt issuance costs and discounts | $53.7K | $239.8K |
| Change in fair value of derivative liabilities | $6.3K | $17.1K |
| Loss (Gain) on extinguishment of debt | -$326.3K | $194.5K |
| Shares issued in exchange for services | $250.0K | |
| Stock-based compensation | $496.9K | |
| Prepaid expenses and other current assets | -$148.5K | -$11.5K |
| Accounts payable- trade | $496.9K | $1.1M |
| Accrued expenses | -$453.4K | $851.3K |
| Accrued interest | $14.2K | $101.3K |
| Net Cash Used In Operating Activities | -$4.8M | -$649.3K |
| Proceeds from issuance of convertible notes payable | $1.0M | |
| Repayment of notes payable- related party | -$275.0K | |
| Proceeds from issuance of common stock and warrants in private placements | $7.2M | |
| Payment of issuance costs related to private placements | -$1.7M | -$193.9K |
| Payment of debt issuance costs | -$127.5K | |
| Net Cash Provided By Financing Activities | $5.2M | $678.6K |
| Net Increase In Cash and Cash Equivalents | $425.1K | $29.3K |
| Interest | $9.6K | |
| Recapitalization of Unite Acquisition 1 Corp. accumulated deficit at time of the exchange | -$279.7K | |
| Common stock cancelled at the time of the exchange | $175 | |
| Convertible notes and accrued interest converted into common stock | $1.7M | |
| Forgiveness of accrued consulting fees by related parties | $345.9K |
No quarter-by-quarter statement was filed.
Corporate structure
ADAPTIN BIO, INC. sits at the top of its group. 1 entity, 1 country on record. Switch between the flow chart and the network, and select any entity to see its details.
Major holders of ADAPTIN BIO, INC.
- Michael J. Roberts Filed SCHEDULE 13D on ADAPTIN BIO, INC., latest Feb 18, 2025
- Simon Pedder Filed SCHEDULE 13D on ADAPTIN BIO, INC., latest Feb 18, 2025
- ADAPTIN BIO, INC. Charlotte, North Carolina
Built from major holders from Schedules 13D and 13G. Each entity in the chart links to its source.
What it owns
What ADAPTIN BIO, INC. reports owning in its annual reports to the SEC: buildings, land and equipment, real estate and locations, investments, intangible assets and inventory, at the end of its latest fiscal year and a year before.
Investments
| Item | Latest | A year before | Change |
|---|---|---|---|
| Cash and cash equivalents | $459.2K5 Dec 31, 2025 | $34.1K5 Dec 31, 2024 | +1247.1% |
Properties, in its own words
Our principal executive office is located in North Carolina under a month-to-month lease arrangement. We currently lease any office space that we use in our operations, and we do not own any real property. We believe that our facility space adequately meets our needs and that we will be able to obtain any additional operating space that may be required on commercially reasonable terms.
Item 2 of the 10-K filed Apr 1, 2026.3
Leadership
Who has led ADAPTIN BIO, INC., and when. Pick a name to see everywhere that person has worked.
Chief executive
Chair
President
Chief financial officer
- Chief executive officerNathan P. Pereira Nov 30, 2023 to Nov 30, 20239
- ChairSimon Pedder Feb 18, 2025 to now10
- PresidentNathan P. Pereira Nov 30, 2023 to Nov 30, 20239
- Chief financial officerTimothy Maness Feb 18, 2025 to now11
- Chief financial officerNathan P. Pereira Nov 30, 2023 to Nov 30, 20239
Board members and other officers (5)
- Chief Development OfficerL. Arthur Hewitt Feb 18, 2025 to now12
- Board memberAnthony P. Zook Feb 18, 2025 to now13
- Board memberJ. Nick Riehle Feb 18, 2025 to now14
- Board memberPatrick Joseph Gallagher Feb 18, 2025 to now15
- Board memberNathan P. Pereira Nov 30, 2023 to Nov 30, 20239
Named in SEC Form D filings
People the company listed in its private-offering notices.
- President and Chief Executive OfficerMichael Roberts named Feb 26, 2025 to Jun 22, 202616
Former names
- Unite Acquisition 1 Corp.Aug 10, 2023 to Feb 13, 20252
Timeline
- Aug 25, 20268-K Other events17
- Apr 6, 20268-K Other events18
- Dec 23, 20258-K Entered a material agreement; Unregistered sale of shares19
- Oct 6, 20258-K Executive or director change; Other events20
- Apr 15, 20258-K Completed an acquisition or sale21
- Apr 9, 20258-K Other events22
- Feb 18, 20258-K Entered a material agreement; Completed an acquisition or sale; Unregistered sale of shares23
- Nov 30, 2023New chief executive Nathan P. Pereira becomes CEO9
Filings
75 filings to the SEC since October 2021: 4 annual reports, 9 quarterly reports, 7 major events, 17 insider forms, 2 large holders, 5 private raises, 31 other. The latest 20:
- Sep 10, 2026424B3 PROSPECTUS EDGAR
- Sep 9, 2026EFFECT EDGAR
- Aug 28, 2026S-1 REGISTRATION STATEMENT EDGAR
- Aug 25, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
- Aug 25, 20268-K CURRENT REPORT EDGAR
- Aug 20, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
- Aug 13, 202610-Q QUARTERLY REPORT EDGAR
- Jul 22, 2026EFFECT EDGAR
- Jul 21, 2026POS AM POST-EFFECTIVE AMENDMENT NO. 1 TO FORM S-1 EDGAR
- Jun 22, 2026D/A EDGAR
- Jun 12, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
- Jun 12, 202610-K/A AMENDMENT NO. 1 TO FORM 10-K EDGAR
- May 18, 2026424B3 PROSPECTUS SUPPLEMENT EDGAR
- May 15, 202610-Q QUARTERLY REPORT EDGAR
- Apr 6, 20268-K CURRENT REPORT EDGAR
- Apr 1, 202610-K ANNUAL REPORT EDGAR
- Apr 1, 2026NT 10-K NOTIFICATION OF LATE FILING EDGAR
- Mar 23, 2026D/A EDGAR
- Feb 20, 2026D/A EDGAR
- Jan 5, 2026D EDGAR
The 75 filings since October 2021 can be filtered by form type and year here when JavaScript is on.
Every filing from the last five years, summarized. The full record is on SEC EDGAR.
Major holders
Investors who own more than 5% of the shares must tell the SEC: a 13D if they may seek to influence the company, a 13G if they hold passively.
- Michael J. RobertsSCHEDULE 13D, 1 filing Feb 18, 202524
- Simon PedderSCHEDULE 13D, 1 filing Feb 18, 202525
Funding
Where the company's money came from, by calendar year: private offerings filed with the SEC, federal grants, loans, contracts and other assistance from USAspending.gov, and PPP loans from the SBA. Each bar links to the records below.
- Private raises (Form D) $15.0M
Figures by year
| Year | Private raises (Form D) | Total |
|---|---|---|
| 2025 | $15.0M | $15.0M |
Private raises
Private offerings the company reported to the SEC on Form D. The amount is what the latest filing says was sold so far, charted in the year of the first sale. Covers filings since Oct 1, 2021.
SEC filer profile
How ADAPTIN BIO, INC. is registered with the Securities and Exchange Commission, from its EDGAR record and the cover page of its latest annual report.
- Name on EDGARADAPTIN BIO, INC.1
- CIK0001938571
- Employer ID (EIN)88-15664153
- Filer statusNon-accelerated filer an emerging growth company; a smaller reporting company; not a shell company3
- Incorporated inDelaware3
- Fiscal year endsDecember 311
- Industry code (SIC)2836 Biological Products, (No Diagnostic Substances)1
- SEC reviewing officeOffice of Life Sciences, Division of Corporation Finance1
- Business address3540 Toringdon Way, Suite 200, #250, Charlotte, NC 282771
- Phone(888) 609-14981
- Shares outstanding9,233,573 as of Aug 11, 20267
- Public float$9.3M as of Jun 30, 20253
- AuditorWithumSmith+Brown, PC, East Brunswick, New Jersey PCAOB ID 100; no auditor attestation of internal control over financial reporting3
- On EDGAR sinceAug 10, 20231
- Filings75 in all: 10-Q (9), 3 (9), 424B3 (9), 4 (8), 8-K (6), CORRESP (4), UPLOAD (4), 10-K (3)1
All 22 form types
D/A (3), EFFECT (3), D (2), NT 10-K (2), S-1 (2), S-1/A (2), SCHEDULE 13D (2), 10-12G (1), 10-12G/A (1), 10-K/A (1), 8-K/A (1), POS AM (1), S-8 (1), SC 14F1 (1)
- Latest filingsAnnual report (10-K) Apr 1, 2026
Quarterly report (10-Q) Aug 13, 2026
Latest 8-K (8-K) Aug 25, 2026
Securities registered for trading
| Class | Symbol | Exchange |
|---|---|---|
| N/A |
From the cover page of the 10-K filed Apr 1, 2026 (Section 12(b) of the Exchange Act).3
Risk factors and legal proceedings
Legal proceedings
We are currently not aware of any pending legal proceedings to which we are a party or of which any of our property is the subject, nor are we aware of any such proceedings that are contemplated by any governmental authority.
The opening of Item 3, Legal Proceedings.3
Sources
The numbers on this page point here. Each one links to the record it came from.
- 1
- 2
- 3
- 4
- 5
- 6
- 7
- 8
- 9
- 10SEC EDGARSimon Pedder, Chair
- 11
- 12
- 13SEC EDGARAnthony P. Zook, Board member
- 14SEC EDGARJ. Nick Riehle, Board member
- 15
- 16
- 17SEC EDGAROther events
- 18SEC EDGAROther events
- 19
- 20
- 21SEC EDGARCompleted an acquisition or sale
- 22SEC EDGAROther events
- 23
- 24
- 25
- 26